Bladder, Neurogenic
9
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
Functional Changes in the Brain After Tibial Nerve Stimulation: a Pilot Study
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies
Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate
A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele